Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates
DeepSLE uses retinal images to identify systemic lupus erythematosus and related complications with high accuracy across diverse populations, outperforming physicians in a prospective comparison.
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.